Aditya Bagrodia

This is Aditya Bagrodia as your host this week. And I'm very excited to introduce our guest today, Raina McKay, who's one of my partners here at UC San Diego. Welcome back to the show, Raina. How are you doing today?

This is Aditya Bagrodia as your host this week. And I'm very excited to introduce our guest today, Raina McKay, who's one of my partners here at UC San Diego. Welcome back to the show, Raina. How are you doing today?

This is Aditya Bagrodia as your host this week. And I'm very excited to introduce our guest today, Raina McKay, who's one of my partners here at UC San Diego. Welcome back to the show, Raina. How are you doing today?

Oh, it's a pleasure, Raina. I literally think every time I interact with you, I get inspired and I get smarter. And, you know, what you're able to do for our team and for the GU community is amazing. And I've got to take this opportunity to throw a little plug in. Raina is on the ballot for the nominating committee for ASCO elections this year.

Oh, it's a pleasure, Raina. I literally think every time I interact with you, I get inspired and I get smarter. And, you know, what you're able to do for our team and for the GU community is amazing. And I've got to take this opportunity to throw a little plug in. Raina is on the ballot for the nominating committee for ASCO elections this year.

Oh, it's a pleasure, Raina. I literally think every time I interact with you, I get inspired and I get smarter. And, you know, what you're able to do for our team and for the GU community is amazing. And I've got to take this opportunity to throw a little plug in. Raina is on the ballot for the nominating committee for ASCO elections this year.

There's literally I don't think anybody who's out there currently that's contributed so much to our field and oncology in general. So if you're a member, get out there and vote for Raina. She's amazing. You don't need me to tell you that. All right, Raina. So this is actually an episode that is kind of backed by request and popular demand.

There's literally I don't think anybody who's out there currently that's contributed so much to our field and oncology in general. So if you're a member, get out there and vote for Raina. She's amazing. You don't need me to tell you that. All right, Raina. So this is actually an episode that is kind of backed by request and popular demand.

There's literally I don't think anybody who's out there currently that's contributed so much to our field and oncology in general. So if you're a member, get out there and vote for Raina. She's amazing. You don't need me to tell you that. All right, Raina. So this is actually an episode that is kind of backed by request and popular demand.

You know, as prostate cancer, both in the localized and advanced contexts, gets more and more complicated, ADT, androgen deprivation therapy, still just holds such a central role. And maybe I'll ask you to just take a little walk down memory lane over the course of your career, how you've thought about ADT, how it maybe it's come more within your wheelhouse than other places.

You know, as prostate cancer, both in the localized and advanced contexts, gets more and more complicated, ADT, androgen deprivation therapy, still just holds such a central role. And maybe I'll ask you to just take a little walk down memory lane over the course of your career, how you've thought about ADT, how it maybe it's come more within your wheelhouse than other places.

You know, as prostate cancer, both in the localized and advanced contexts, gets more and more complicated, ADT, androgen deprivation therapy, still just holds such a central role. And maybe I'll ask you to just take a little walk down memory lane over the course of your career, how you've thought about ADT, how it maybe it's come more within your wheelhouse than other places.

Can you share a little bit on that?

Can you share a little bit on that?

Can you share a little bit on that?

Totally. And you know, I think as fortunately, in my opinion, as advanced prostate cancer management has gotten more complex, really digging into side effects, mitigating those side effects, explaining those side effects. You know, early on as a urology trainee, it was like, all right, we're gonna start you on Lupron. And the counseling might've been, you know, you might have some hot flashes.

Totally. And you know, I think as fortunately, in my opinion, as advanced prostate cancer management has gotten more complex, really digging into side effects, mitigating those side effects, explaining those side effects. You know, early on as a urology trainee, it was like, all right, we're gonna start you on Lupron. And the counseling might've been, you know, you might have some hot flashes.

Totally. And you know, I think as fortunately, in my opinion, as advanced prostate cancer management has gotten more complex, really digging into side effects, mitigating those side effects, explaining those side effects. You know, early on as a urology trainee, it was like, all right, we're gonna start you on Lupron. And the counseling might've been, you know, you might have some hot flashes.

Okay, we'll see you in six months with a PSA and a testosterone. And I'd like to think that, you know, it's a bit more advanced than that. So maybe you kind of alluded to it, you know, obviously this is prostate cancer. It is addicted to testosterone. We've got to get those testosterone level down to castrate.

Okay, we'll see you in six months with a PSA and a testosterone. And I'd like to think that, you know, it's a bit more advanced than that. So maybe you kind of alluded to it, you know, obviously this is prostate cancer. It is addicted to testosterone. We've got to get those testosterone level down to castrate.